Few technologies blur the line between medicine and science fiction like the artificial womb.
As East Asia’s largest economies confront collapsing birth rates, a tempting question follows: could gestation outside the body eventually reverse demographic decline and the economic challenges it threatens?
In response to declining populations in many OECD countries, some analysts are openly discussing the use of artificial wombs to boost birth rates and prevent the economic consequences of demographic decline. Based on the current state of science, the honest answer is no, and understanding why requires separating what exists from what remains hypothetical.
Where the science actually stands
The leading device is EXTEND, the “Biobag” developed at the Children’s Hospital of Philadelphia (CHOP). In a landmark 2017 study, the team sustained fetal lambs for up to four weeks in a fluid-filled bag connected to a pumpless oxygenator through the umbilical vessels. The animals were developmentally equivalent to human infants at roughly 24 weeks — the generally recognised threshold of viability.
Two caveats matter. First, a 2025 – 2026 systematic review notes that this four-week result remains a single landmark rather than a reproducible standard, while parallel work in Australia and Japan has sustained smaller lambs for up to 336 hours (14 days).
Second, the central obstacle to human use is technical: reliably cannulating the umbilical vessels of an extremely small fetus.
Crucially, the researchers are not building a baby-making machine. CHOP lead author Jennifer Cohen states that EXTEND “will not be used to make a non-viable pregnancy viable,” but rather to help extremely premature babies survive with less harm.
Partial versus complete: the decisive distinction
This is where popular coverage misleads. Ectogestation (partial) extends an already established pregnancy to help extreme preemies survive. Complete ectogenesis — growing a child from conception to term entirely outside a body — is the only version that could affect birth rates, and it does not exist.
Reproducing implantation, a full placenta, and maternal hormonal signalling remains far beyond current capability. Tellingly, the viral 2025 claim of a Chinese “pregnancy robot” from Kaiwa Technology was fact-checked as false, including the supposed inventor’s very existence.
Even if the technology were available, the demographic premise is flawed. South Korea’s fertility rate hit 0.72 in 2023 (the world’s lowest) against a replacement level of 2.1. Japan stands at around 1.3, while China is close to 1.0. At a fertility rate of 0.7, a population contracts by roughly one birth for every fifteen deaths.
But the drivers are economic and social, not gestational. People are not deterred primarily by the biology of pregnancy; they are deterred by geopolitical uncertainty, inflationary pressures fueled by surging oil prices, rising living costs, career pressures, childcare burdens, and shifting marriage patterns.
Japan already spends around 1% of GDP on family policy for a projected gain of just 0.05 – 0.1 points in the fertility rate, and modelling gives it only a 12% chance of reversing the decline by 2030. An artificial womb externalises nine months of gestation; it does nothing to address the decades-long financial and personal commitment of raising a child.
The technology is real and advancing, but its trajectory toward neonatal intensive care, not population policy. As an economic remedy, it is the wrong tool for the wrong problem.
